Vascular endothelial growth factor: a neurovascular target in neurological diseases (Q38882640)

7 September 2017

1 reference

title

Vascular endothelial growth factor: a neurovascular target in neurological diseases (English)

1 reference

7 September 2017

0 references

5

Peter Carmeliet

1 reference

7 September 2017

Christian Lange

1

1 reference

7 September 2017

Erik Storkebaum

series ordinal

2

1 reference

7 September 2017

Carmen Ruiz de Almodóvar

series ordinal

3

1 reference

7 September 2017

Mieke Dewerchin

series ordinal

4

1 reference

7 September 2017

language of work or name

English

0 references

publication date

1 July 2016

1 reference

7 September 2017

Nature Reviews Neurology

1 reference

7 September 2017

12

1 reference

7 September 2017

439-454

1 reference

7 September 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2016.88

7 September 2017

0 references

cites work

Signal transduction by vascular endothelial growth factor receptors

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Role and therapeutic potential of VEGF in the nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

The role of vascular endothelial growth factor and vascular stability in diseases of the ear.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Placental growth factor in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

The future of antiangiogenic treatment in glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Molecular mechanisms and clinical applications of angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Ten years of anti-vascular endothelial growth factor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Delineating multiple functions of VEGF-A in the adult brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Identification and characterization of VEGF and FGF from Hydra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Diverse roles for VEGF-A in the nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

The neurovascular link in health and disease: molecular mechanisms and therapeutic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

The neural tube patterns vessels developmentally using the VEGF signaling pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Neurovascular development uses VEGF-A signaling to regulate blood vessel ingression into the neural tube

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vessel maturation schedule determines vulnerability to neuronal injuries of prematurity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor-A specifies formation of native collaterals and regulates collateral growth in ischemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Formation of the collateral circulation is regulated by vascular endothelial growth factor-A and a disintegrin and metalloprotease family members 10 and 17.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Matrix-binding vascular endothelial growth factor (VEGF) isoforms guide granule cell migration in the cerebellum via VEGF receptor Flk1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor controls neuronal migration and cooperates with Sema3A to pattern distinct compartments of the facial nerve

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF signaling through neuropilin 1 guides commissural axon crossing at the optic chiasm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF mediates commissural axon chemoattraction through its receptor Flk1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Establishment and Dysfunction of the Blood-Brain Barrier

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

The changing scene of amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Emerging mechanisms of molecular pathology in ALS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Amyotrophic lateral sclerosis: a neurovascular disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Impaired Autonomic Regulation of Resistance Arteries in Mice With Low Vascular Endothelial Growth Factor or Upon Vascular Endothelial Growth Factor Trap Delivery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Alterations of the blood-spinal cord barrier in sporadic amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF-induced activation of the PI3-K/Akt pathway reduces mutant SOD1-mediated motor neuron cell death.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor protects motoneurons from serum deprivation-induced cell death through phosphatidylinositol 3-kinase-mediated p38 mitogen-activated protein kinase inhibition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF protects motor neurons against excitotoxicity by upregulation of GluR2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor prevents G93A-SOD1-induced motor neuron degeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Intramuscular administration of a VEGF zinc finger transcription factor activator (VEGF-ZFP-TF) improves functional outcomes in SOD1 rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor prevents paralysis and motoneuron death in a rat model of excitotoxic spinal cord neurodegeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Alzheimer's dementia by circulation disorders: when trees hide the forest.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular dysfunction in the pathogenesis of Alzheimer's disease--A review of endothelium-mediated mechanisms and ensuing vicious circles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

The neuropathology and cerebrovascular mechanisms of dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

The genetic landscape of Alzheimer disease: clinical implications and perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Adjusting the compass: new insights into the role of angiogenesis in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Does vascular pathology contribute to Alzheimer changes?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular contributions to cognitive impairment and dementia including Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Alzheimer's beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Abeta peptides accelerate the senescence of endothelial cells in vitro and in vivo, impairing angiogenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Decreased release of the angiogenic peptide vascular endothelial growth factor in Alzheimer's disease: recovering effect with insulin and DHEA sulfate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Low serum VEGF levels are associated with Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Decreased serum levels of the angiogenic factors VEGF and TGF-β1 in Alzheimer's disease and amnestic mild cognitive impairment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Expression of vascular endothelial growth factor (VEGF) mRNA, VEGF receptor 2 (Flk-1) mRNA, and of VEGF co-receptor neuropilin (Nrp)-1 mRNA in brain tissue of aging Tg2576 mice by in situ hybridization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Huntington disease: pathogenesis and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Treating the whole body in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF-releasing biodegradable nanospheres administered by craniotomy: a novel therapeutic approach in the APP/Ps1 mouse model of Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Therapeutic effects of the transplantation of VEGF overexpressing bone marrow mesenchymal stem cells in the hippocampus of murine model of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Evaluating the SERCA2 and VEGF mRNAs as Potential Molecular Biomarkers of the Onset and Progression in Huntington's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Dose-dependent neuroprotection of VEGF₁₆₅ in Huntington's disease striatum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Blood-brain barrier dysfunction in parkinsonian midbrain in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Neuronal vascular relationships in the zona compacta of normal and parkinsonian substantia nigra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular degeneration in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Impairment of brain vessels may contribute to mortality in patients with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Favorable effects of VEGF gene transfer on a rat model of Parkinson disease using adeno-associated viral vectors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Neurorescue effects of VEGF on a rat model of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Mesenchymal stem cells and neuroregeneration in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Subthalamic nucleus neuronal firing rate increases with Parkinson's disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Spinal cord stimulation exerts neuroprotective effects against experimental Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Pathogenesis of diabetic neuropathy: focus on neurovascular mechanisms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Advanced glycation end-products induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood-nerve barrier by stimulating the release of TGF-β and vascular endothelial growth factor (VEGF) by pericytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Reversal of experimental diabetic neuropathy by VEGF gene transfer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Microvessel permeability correlates with diabetic peripheral neuropathy in early stage of streptozotocin-induced diabetes rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Neutralization of schwann cell-secreted VEGF is protective to in vitro and in vivo experimental diabetic neuropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Therapeutic potential of VEGF and VEGF-derived peptide in peripheral neuropathies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor-A165b prevents diabetic neuropathic pain and sensory neuronal degeneration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Effects of vascular endothelial growth factor in ischemic stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Hippocampal neurogenesis after traumatic brain injury is mediated by vascular endothelial growth factor receptor-2 and the Raf/MEK/ERK cascade.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Pronounced hypoxia in the subventricular zone following traumatic brain injury and the neural stem/progenitor cell response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Long-term neuroblast migration along blood vessels in an area with transient angiogenesis and increased vascularization after stroke.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Release of VEGF and FGF in the extracellular space following severe subarachnoidal haemorrhage or traumatic head injury in humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Serum brain-derived neurotrophic factor and vascular endothelial growth factor levels are associated with risk of stroke and vascular brain injury: Framingham Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Peri-infarct blood-brain barrier dysfunction facilitates induction of spreading depolarization associated with epileptiform discharges.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Inhalation of nitric oxide prevents ischemic brain damage in experimental stroke by selective dilatation of collateral arterioles.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Microvascular plasticity after experimental stroke: a molecular and MRI study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factors (VEGFs) and stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor increases neurogenesis after traumatic brain injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Increased expression of vascular endothelial growth factor attenuates contusion necrosis without influencing contusion edema after traumatic brain injury in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Comparison of vascular growth factors in the murine brain reveals placenta growth factor as prime candidate for CNS revascularization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Treatment of traumatic brain injury using zinc-finger protein gene therapy targeting VEGF-A.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Neuroprotective Effect of VEGF-Mimetic Peptide QK in Experimental Brain Ischemia Induced in Rat by Middle Cerebral Artery Occlusion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Neuron-specific prolyl-4-hydroxylase domain 2 knockout reduces brain injury after transient cerebral ischemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Inhibition of HIF prolyl-4-hydroxylases by FG-4497 reduces brain tissue injury and edema formation during ischemic stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Inhibition of prolyl hydroxylases by dimethyloxaloylglycine after stroke reduces ischemic brain injury and requires hypoxia inducible factor-1α.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Deletion or Inhibition of the Oxygen Sensor PHD1 Protects against Ischemic Stroke via Reprogramming of Neuronal Metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

The Oxygen Sensor PHD2 Controls Dendritic Spines and Synapses via Modification of Filamin A

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Cell-based therapy for ischemic stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Preconditioning with VEGF Enhances Angiogenic and Neuroprotective Effects of Bone Marrow Mononuclear Cell Transplantation in a Rat Model of Chronic Cerebral Hypoperfusion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor (VEGF) in seizures: a double-edged sword

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Blood-brain barrier disruption results in delayed functional and structural alterations in the rat neocortex.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Development, maintenance and disruption of the blood-brain barrier

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Epileptiform activity induces vascular remodeling and zonula occludens 1 downregulation in organotypic hippocampal cultures: role of VEGF signaling pathways.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor attenuates status epilepticus-induced behavioral impairments in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF receptor-2 (Flk-1) overexpression in mice counteracts focal epileptic seizures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Blood-brain barrier disruption is more severe in neuromyelitis optica than in multiple sclerosis and correlates with clinical disability.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Blood-brain barrier disruption in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Sera from neuromyelitis optica patients disrupt the blood-brain barrier.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Bevacizumab diminishes experimental autoimmune encephalomyelitis by inhibiting spinal cord angiogenesis and reducing peripheral T-cell responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Optimizing the Anti-VEGF Treatment Strategy for Neovascular Age-Related Macular Degeneration: From Clinical Trials to Real-Life Requirements

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research Network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Transgenic ablation of doublecortin-expressing cells suppresses adult neurogenesis and worsens stroke outcome in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Temporally specified genetic ablation of neurogenesis impairs cognitive recovery after traumatic brain injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Adult hippocampal neural stem and progenitor cells regulate the neurogenic niche by secreting VEGF.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF links hippocampal activity with neurogenesis, learning and memory

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF is necessary for exercise-induced adult hippocampal neurogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Inhibition of VEGF receptor 2 increased cell death of dentate hilar neurons after traumatic brain injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Reversible modulations of neuronal plasticity by VEGF.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Macrophage-Induced Blood Vessels Guide Schwann Cell-Mediated Regeneration of Peripheral Nerves.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Activating Injury-Responsive Genes with Hypoxia Enhances Axon Regeneration through Neuronal HIF-1α.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Mechanisms of age-related macular degeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Generation of transgenic mice with mild and severe retinal neovascularisation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Long-term global retinal microvascular changes in a transgenic vascular endothelial growth factor mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Early vascular and neuronal changes in a VEGF transgenic mouse model of retinal neovascularization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1α-VEGF pathway inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.88

Neurovascular signalling defects in neurodegeneration

31 March 2020

1 reference

12 December 2020

VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma

1 reference

12 December 2020

VEGF: a critical player in neurodegeneration

1 reference

12 December 2020

Blood vessels change in the mesencephalon of patients with Parkinson's disease.

1 reference

12 December 2020

Pathologic alterations in the diabetic neuropathies of humans: a review

1 reference

12 December 2020

Effects of asiaticoside on human umbilical vein endothelial cell apoptosis induced by Aβ1-42.

1 reference

12 December 2020

Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis

1 reference

12 December 2020

Vascular endothelial growth factor protects cultured rat hippocampal neurons against hypoxic injury via an antiexcitotoxic, caspase-independent mechanism

1 reference

12 December 2020

Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEUROL.2016.88

1 reference

Dimensions Publication ID

7 September 2017

0 references

1 reference